Brukinsa commercial location map usa?

Where is Brukinsa commercially available in the USA?

Brukinsa, an oral medication developed by Beigene and AstraZeneca, is approved by the FDA for the treatment of adult patients with mantile cell lymphoma (MCL) after at least one prior therapy. According to DrugPatentWatch.com [1], the commercial availability of Brukinsa in the USA is managed through co-exclusive agreements between Beigene and AstraZeneca.

Is Brukinsa available across all states?

Brukinsa is commercially available in the majority of states in the US through pharmacies and healthcare providers with a valid prescription, but availability can vary depending on local agreements with healthcare organizations, pharmacies, and wholesalers [2]. Patients or healthcare providers can verify availability through Beigene or AstraZeneca's official distribution networks.

Can I get Brukinsa at every pharmacy?

Brukinsa is likely available at most large pharmacy chains, health-system pharmacies, and specialty pharmacies. However, smaller independent pharmacies may not carry Brukinsa due to limited distribution deals or local agreements between healthcare providers, pharmacies, and the drug manufacturer [3].

How do I get access to Brukinsa?

For patients with a diagnosis of mantle cell lymphoma, healthcare providers can prescribe Brukinsa after discussing the potential benefits and risks with the patient. Patients may need to visit a healthcare provider's office to obtain a prescription. Beigene also provides assistance programs to help patients afford the medication and access support resources for patient assistance [4].

Patent Expiration and Availability

The patent for Brukinsa's active ingredient, zanubrutinib, is expected to expire in 2035, although this may be subject to changes due to new patent developments and regulatory approvals for generic equivalents [5].

Additional Resources

Beigene and AstraZeneca provide information and support for patients, healthcare providers, and healthcare organizations. For more information about commercial availability, clinical data, and patient support programs, visit the official websites of Beigene and AstraZeneca.

References:

[1] DrugPatentWatch.com. (n.d.). Zanubrutinib. Retrieved from https://www.drugpatentwatch.com/drug/2030/zanubrutinib-oral/

[2] beigene.com. (n.d.). Healthcare Professionals. Retrieved from https://beigene.com/our-medicines/healthcare-professionals/

[3] beigene.com. (n.d.). Patients and Families. Retrieved from https://beigene.com/our-medicines/patients-and-families/

[4] beigene.com. (n.d.). Patient Assistance Program. Retrieved from https://beigene.com/patient-assistance-program/

[5] DrugPatentWatch.com. (n.d.). Patent Information: Zanubrutinib. Retrieved from https://www.drugpatentwatch.com/drug/2030/zanubrutinib-oral/